AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic

$SXTC

China SXT Pharmaceuticals, Inc.

Price · $SXTCvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $SXTC in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $SXTC in the last 30 days.

See all $SXTC insider activity →
Top stories · $SXTCMore →
AUG 18·stockstotrade.comMed

SXTC Stock Rockets On Massive Reverse Split Volatility

China SXT Pharmaceuticals Inc. (SXTC) shares surged 28.78% on August 18, 2026, driven by investor optimism and speculative trading. The stock's recent volatility follows a significant price jump from $0.06–$0.12 in late July to $3–$5 in mid-August, likely due to a reverse stock split. The company reported $1.14M in revenue, $34.8M in total assets, and $28.2M in cash, with a price-to-book ratio of 0.07 and negative return on capital. Traders are focusing on the stock's volatile price action rathe

JUL 23·investing.com

China SXT Pharmaceuticals stock drops on $9M share offering By Investing.com

China SXT Pharmaceuticals (NASDAQ:SXTC) shares fell 77% after it announced a $9 million registered direct offering. The company will sell 4.5 million units at $2.00 each, with each unit including one Class A share and a warrant exercisable at $3.20, expiring in one year. Closing is expected around July 24, 2025.

JUN 2·benzinga.com

Benzinga

China SXT Pharmaceuticals said in an SEC filing it may sell up to $100 million of Class A ordinary shares under an at-the-market program, issuing shares from time to time on Nasdaq or other venues. Univest Securities will act as sales agent and receive a 3% commission plus certain expenses. The stock closed at $1.68 (+0.60%) and rose 25.6% after hours to $2.11.

SXTC sentiment & insider activity

Recent SXTC coverage spans market movers, financial news and corporate actions.

What's driving SXTC

  • The move is framed as reverse-split-driven micro-cap volatility rather than a fundamental catalyst, implying elevated short-term trading risk and momentum churn.

    stockstotrade.com · Aug 18, 2026

  • The registered direct offering at $2.00 per unit with immediately exercisable warrants is a near-term dilution overhang.

    investing.com · Jul 23, 2026

  • ATM equity sales raise near-term dilution/overhang risk, but the after-hours pop suggests traders are initially focusing on funding optionality.

    benzinga.com · Jun 2, 2026

  • The share re-classification introduces a dual-class share structure, potentially affecting voting power and shareholder control. This change may influence investor sentiment and stock performance.

    GlobeNewswire · Mar 23, 2026

  • China SXT Pharmaceuticals (SXTC) reported unaudited financial results for H1 2025, highlighting reliance on a China-based VIE structure and associated regulatory, capital control, and tax risks. The company’s somewhat-bearish sentiment suggests cautious investor outlook.

    TipRanks · Jan 1, 2026

AlphAI scores every news story that mentions SXTC with an AI model for sentiment and relevance, and aggregates insider trades from China SXT Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SXTC

Score
AUG 18$SXTCMedstockstotrade.com

SXTC Stock Rockets On Massive Reverse Split Volatility

China SXT Pharmaceuticals Inc. (SXTC) shares surged 28.78% on August 18, 2026, driven by investor optimism and speculative trading. The stock's recent volatility follows a significant price jump from $0.06–$0.12 in late July to $3–$5 in mid-August, likely due to a reverse stock split. The company reported $1.14M in revenue, $34.8M in total assets, and $28.2M in cash, with a price-to-book ratio of 0.07 and negative return on capital. Traders are focusing on the stock's volatile price action rathe

4 min read
JUN 2$SXTCMedAI 9/10benzinga.com

Benzinga

China SXT Pharmaceuticals said in an SEC filing it may sell up to $100 million of Class A ordinary shares under an at-the-market program, issuing shares from time to time on Nasdaq or other venues. Univest Securities will act as sales agent and receive a 3% commission plus certain expenses. The stock closed at $1.68 (+0.60%) and rose 25.6% after hours to $2.11.

4 min read
MAR 23$SXTCMedGlobeNewswire

China SXT Pharmaceuticals, Inc. Announces Share Re-classification

China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) announced a share re-classification, effective March 24, 2026, which will introduce a dual-class share structure. The re-classification was approved by shareholders on July 28, 2025, establishing Class A Ordinary Shares with no par value and Class B Ordinary Shares entitling holders to fifty votes per share. Existing shares held through nominees will be automatically adjusted to reflect this change.

2 min read
JAN 1$SXTCLowTipRanks

China SXT Pharmaceuticals Files First-Half 2025 Financial Results on Form 6-K

China SXT Pharmaceuticals (SXTC) filed a Form 6-K on December 31, 2025, disclosing unaudited financial results for the first half of 2025, covering the period ended September 30, 2025. The company highlighted its continued reliance on a China-based VIE structure and noted significant regulatory, capital control, and tax risks that could impact its control over the VIE and its ability to remit dividends to investors. These factors pose key risks for investors and stakeholders.

3 min read

Related tickers

More in Drug Manufacturers - Specialty & Generic